我们可以使用终语阿诸那吗?新型口服抗凝剂(NOACs)在covid -19后心脏病中的应用?

IF 0.4 Q4 PHARMACOLOGY & PHARMACY

Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2022-03-01 DOI:10.1177/0976500X221080202

S. Dwivedi, Vinod Sharma, C. Patil

{"title":"我们可以使用终语阿诸那吗?新型口服抗凝剂(NOACs)在covid -19后心脏病中的应用?","authors":"S. Dwivedi, Vinod Sharma, C. Patil","doi":"10.1177/0976500X221080202","DOIUrl":null,"url":null,"abstract":"Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons AttributionNonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-Commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https:// us.sagepub.com/en-us/nam/open-access-at-sage). Research Letter","PeriodicalId":16761,"journal":{"name":"Journal of Pharmacology & Pharmacotherapeutics","volume":"13 1","pages":"95 - 96"},"PeriodicalIF":0.4000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Can We Use Terminalia Arjuna (Roxb.) Wight and Arn in Place of Novel Oral Anticoagulants (NOACs) in Post-COVID-19Cardiac Conditions?\",\"authors\":\"S. Dwivedi, Vinod Sharma, C. Patil\",\"doi\":\"10.1177/0976500X221080202\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons AttributionNonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-Commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https:// us.sagepub.com/en-us/nam/open-access-at-sage). Research Letter\",\"PeriodicalId\":16761,\"journal\":{\"name\":\"Journal of Pharmacology & Pharmacotherapeutics\",\"volume\":\"13 1\",\"pages\":\"95 - 96\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2022-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacology & Pharmacotherapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/0976500X221080202\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacology & Pharmacotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/0976500X221080202","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

知识共享非商业CC BY-NC：本文根据知识共享属性非商业4.0许可条款分发(http://www.creativecommons.org/licenses/by-nc/4.0/)其允许作品的非商业使用、复制和分发，而无需进一步许可，前提是原始作品按照SAGE和开放访问页面（https://us.sagepub.com/en-us/nam/Open-Access-at-SAGE）的规定进行归属。研究信函

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Can We Use Terminalia Arjuna (Roxb.) Wight and Arn in Place of Novel Oral Anticoagulants (NOACs) in Post-COVID-19Cardiac Conditions?

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons AttributionNonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-Commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https:// us.sagepub.com/en-us/nam/open-access-at-sage). Research Letter

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Pharmacology & Pharmacotherapeutics PHARMACOLOGY & PHARMACY-

CiteScore

0.40

自引率

0.00%

发文量